By using our site you accept the terms of our cookie policy

Khang LLP Announces an Investigation of Spectrum Pharmaceuticals

October 12, 2016

Image

Khang & Khang LLP Announces an Investigation of Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible violations of federal securities laws.

If you purchased shares of Spectrum and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected]

The investigation focuses on a statement by Spectrum that it failed to disclose that the Food & Drug Administration advised it to not submit a New Drug Application for its drug candidate apaziquone back in December of 2012.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected]

Contact Us

+44 (0) 203 725 6841